Shuaibing Jiang and Jianyu Li — McGill bioengineering and Mass General Brigham postdoctoral — published the click-clotting paper in Nature on April 29: a cytogel that crosslinks red blood cells via a bioorthogonal click reaction, forms a solid gel in under five seconds, exceeds native clots by 13x in fracture toughness and 4x in adhesion energy, and outperformed the clinically used hemostatic product in rodent liver hemorrhage. [1][2] Yesterday's paper carried the prep-time arithmetic — autologous clots in 20 minutes, allogeneic in 10 — as the translational news; today the trauma-pipeline read sharpens against the budget context. The cytogel chemistry doesn't interfere with native coagulation; the engineered material embeds in the body's own fibrin clot, with minimal immune reactivity and no toxicity in major organs. The U.S. Department of Defense Joint Trauma System and the NIH National Heart, Lung, and Blood Institute are the two federal funders most likely to move the platform toward IND, and both face FY2026 cardiology and combat-casualty research cuts that the May 7 paper named explicitly. The bench has produced the result; the pipeline now runs through a thinner appropriations base.

-- KENJI NAKAMURA, Tokyo